Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 16/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 9/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14130136 | 0.89 | NPC1 (0.39) | AVPR2AVPR1AMEN1KMT2A | |
| SCHEMBL14130371 | 0.88 | HCRTR2 (0.40) | AVPR2AVPR1A | |
| SCHEMBL14130169 | 0.87 | AVPR2 (0.41) | AVPR2AVPR1AMEN1KMT2A | |
| SCHEMBL14130015 | 0.87 | PTGIR (0.37) | AVPR2AVPR1AMEN1KMT2A | |
| SCHEMBL14130019 | 0.86 | AVPR2 (0.42) | AVPR2AVPR1ALMNAMEN1KMT2A | |
| SCHEMBL14130356 | 0.86 | AVPR2 (0.45) | AVPR2AVPR1AOXTR | |
| SCHEMBL14130368 | 0.86 | THRB (0.39) | AVPR2AVPR1AMEN1KMT2AOXTR | |
| SCHEMBL14129998 | 0.86 | GHSR (0.42) | AVPR2AVPR1AALDH1A1MEN1KMT2A | |
| SCHEMBL14130361 | 0.86 | HCRTR1 (0.40) | AVPR2AVPR1AMEN1KMT2A | |
| SCHEMBL14130355 | 0.86 | LMNA (0.40) | AVPR2ALDH1A1LMNAHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161294-A1 | Urea derivative, medicinal composition containing the same, and medicinal use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-20080161294-A1 | Urea derivative, medicinal composition containing the same, and medicinal use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1867639-A1 | UREA DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE OF THESE | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161294-A1 | Urea derivative, medicinal composition containing the same, and medicinal use of these | AVPR2, UTS2R, GPR119 | AVPR2 1/4885AVPR1A 4/4885ALDH1A1 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.